RSP Systems

Danish company RSP Systems selected Innokas Medical to produce a prototype of the non-invasive glucose monitoring device

As part of its Scandinavian growth strategy, Innokas Medical has in recent years particularly focused on the growth company segment, resulting in new customers not only from Finland, but also from Norway and Sweden. The partnership with innovative Danish company RSP Systems now completes a hat-trick of the Scandinavian countries and is a significant step in developing Innokas’ position on the Nordic market. The development of RSP’s GlucoBeam® product offers exciting possibilities for the future.

Innokas Medical first made contact with RSP Systems in October 2015 after travelling to Odense, Denmark, to participate in the annual WHINN – Week of Health and Innovation event, where Finpro regularly promotes Finnish healthtech companies.

“RSP Systems did not attend the event but was located in Odense, so we took the opportunity to visit them. By the time we met again six months later, RSP had good results from their research and were already thinking about developing and productizing the next version of the device”, says Antti Virtanen, Account Manager at Innokas Medical.

“We chose Innokas Medical because of its long-term experience with the design and manufacturing of medical devices.”

Stefan O. Banke
Co-Founder & CTO, RSP Systems

In May 2017, RSP Systems selected Innokas Medical to produce a prototype of the GlucoBeam® device, working on its overall mechanical design and electronics.

“We chose Innokas Medical because of its long-term experience with the design and manufacturing of medical devices”, says Stefan O. Banke, co-founder and CTO of RSP Systems.

“We have found that there is a good understanding of RSP’s needs and a willingness to be flexible when needed. It is a really difficult project to take on and needs a high level of communication between the two parties.”

The number of people suffering from diabetes globally is currently 450 million and growing. According to Virtanen, about two hundred FDA applications for non-invasive glucose measurement have been rejected over the years, so the success of the GlucoBeam® product would represent a major breakthrough.

The technology behind GlucoBeam® is based on Raman spectroscopy which enables the painless monitoring of diabetes patients’ glucose levels by measuring the tissue fluid surrounding the cells of the body.

“Nobody is satisfied with the current invasive technology, so non-invasive glucose monitoring is extremely attractive”, explains Banke.